In this issue:
Updated MRD guidelines
DAGO2 versus CPX
TFR rates for CML patients
Efficacy and safety of venetoclax plus cytarabine and mitoxantrone
MUD compared to MMUD
Continuous treatment or fixed duration
BR and SPMs
Clinical activity and tolerability of ibrutinib plus venetoclax
Success rates of drug development and clinical trials
Lisocabtagene maraleucel for relapsed or refractory MZL
Please login below to download this issue (PDF)